<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03298802</url>
  </required_header>
  <id_info>
    <org_study_id>16-0280</org_study_id>
    <nct_id>NCT03298802</nct_id>
  </id_info>
  <brief_title>Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide</brief_title>
  <official_title>Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postpartum prophylactic HCTZ administration for prevention and relapse of preeclampsia or
      gestational hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate effectiveness of hydrochlorothiazide prophylaxis on prophylaxis, prevention and
      relapse of preeclampsia or gestational hypertension on readmission rates, need for additional
      antihypertensive therapy and number of triage visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2017</start_date>
  <completion_date type="Anticipated">May 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blind randomized placebo controlled clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Randomization will be performed by a person not involved in the clinical trial using a computer random list of numbers generated using STATA (StataCorp 14.0, Dallas, TX). This list of random number assignments will be kept secure and sent directly to the investigational drug service (IDS), who will be responsible for the allocation and dispensing of the medications</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of readmission and/or triage visits</measure>
    <time_frame>1-6 weeks postpartum</time_frame>
    <description>Any visit in the hospital</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Need for additional antihypertensive therapy</measure>
    <time_frame>1-6 weeks postpartum</time_frame>
    <description>Requiring additional antihypertensive agents in the postpartum period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>1-6 weeks postpartum</time_frame>
    <description>Days that patient required to be in-house in the postpartum period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Additional doses of anti-hypertensive therapy</measure>
    <time_frame>1-6 weeks postpartum</time_frame>
    <description>Addition of total doses that patient received in the postpartum period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elevation of blood pressure &gt;150/90</measure>
    <time_frame>1-6 weeks postpartum</time_frame>
    <description>Hypertension definition in the postpartum period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe composite maternal morbidity</measure>
    <time_frame>1-6 weeks postpartum</time_frame>
    <description>o Any of the following: ICU admission, HELLP syndrome, eclampsia, stroke, renal failure, pulmonary edema, cardiomyopathy or maternal death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of resources</measure>
    <time_frame>1-6 weeks postpartum</time_frame>
    <description>hospital stay, postpartum clinic or emergency room visit within 4-6 weeks of delivery, need for imaging or other invasive procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1-6 weeks Postpartum</time_frame>
    <description>Allergic reactions (anaphylaxis, angioedema, skin rashes including Stevens Johnson and Toxic Epidermal necrolysis)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">612</enrollment>
  <condition>Pre-Eclampsia</condition>
  <condition>Gestational Hypertension</condition>
  <condition>Superimposed Pre-Eclampsia</condition>
  <condition>Hypertension, Pregnancy-Induced</condition>
  <condition>Postpartum Pregnancy-Induced Hypertension</condition>
  <condition>Postpartum Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Hydrochlorothiazide 50mg Tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for fourteen days postpartum</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide 50mg Tablet</intervention_name>
    <description>Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.</description>
    <arm_group_label>Hydrochlorothiazide 50mg Tablet</arm_group_label>
    <other_name>HydroDIURIL, Microzide, Esidrix, Oretic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablet</intervention_name>
    <description>Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum</description>
    <arm_group_label>Placebo Tablet</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Maternal age â‰¥ 18 years and &lt;50 years.

          -  Diagnosis of gestational hypertension* or preeclampsia^ at any time during pregnancy,
             labor or postpartum.

               -  defined as isolated systolic BP of 140 mm Hg or greater, a diastolic BP of 90 mm
                  Hg or greater, or both) or ^ defines as new-onset hypertension plus new-onset
                  proteinuria, or in the absence of proteinuria, preeclampsia is diagnosed as
                  hypertension in association with thrombocytopenia (platelet count less than
                  100,000/microliter), impaired liver function (elevated blood levels of liver
                  transaminases to twice the normal concentration), the new development of renal
                  insufficiency (elevated serum creatinine greater than 1.1 mg/dL or a doubling of
                  serum creatinine in the absence of other renal disease), pulmonary edema, or
                  new-onset cerebral or visual disturbances.)

        Exclusion Criteria:

          -  Subject requiring antihypertensive therapy at time of screening.

          -  Planned discharge with oral anti-hypertensive medication.

          -  Contraindication to hydrochlorothiazide (advanced renal failure or anuria,
             hypersensitivity to sulfonamides).

          -  Subject not able to follow up postpartum.

          -  Lactose intolerance.

          -  Pre-gestational diabetes.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women after delivery of neonate</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Saad, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTMB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luis A Monsivais, M.D.</last_name>
    <phone>9562926223</phone>
    <email>lamonsiv@utmb.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Violetta Lozovyy, M.D.</last_name>
    <phone>2146005015</phone>
    <email>vilozovy@utmb.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Luis Monsivais</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Saad, MD</last_name>
      <phone>409-747-6646</phone>
      <email>afsaad@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Luis Monsivais, MD</last_name>
      <phone>9562926223</phone>
      <email>lamonsiv@UTMB.EDU</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2017</study_first_submitted>
  <study_first_submitted_qc>September 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2017</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Medical Branch, Galveston</investigator_affiliation>
    <investigator_full_name>Antonio Saad</investigator_full_name>
    <investigator_title>Assistant Professor UTMB</investigator_title>
  </responsible_party>
  <keyword>readmission</keyword>
  <keyword>triage visit for pregnancy related hypertension</keyword>
  <keyword>hydrochlorothiazide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

